Bazedoxifene

• CAT Number: I002519
• CAS Number: 198481-32-2
• Molecular Formula: C30H34N2O3
• Molecular Weight: 470.6
• Purity: ≥95%
• Target: Estrogen/progestogen Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C

Bazedoxifene (CAT: I002519) is a selective estrogen receptor modulator (SERM) that is being investigated for its potential use in the prevention and treatment of osteoporosis. As a SERM, bazedoxifene selectively binds to estrogen receptors and exerts estrogen-like effects in some tissues, while acting as an antagonist in others. It has been shown to inhibit bone resorption and preserve bone density, making it a promising candidate for osteoporosis management. Bazedoxifene is being evaluated in clinical trials to assess its efficacy, safety, and long-term effects on bone health.

Reference

1:Molecular mechanisms mediating the neuroprotective role of the selective estrogen receptor modulator, bazedoxifene, in acute ischemic stroke: a comparative study with 17β-estradiol. Jover-Mengual T, Castelló-Ruiz M, Burguete MC, Jorques M, López-Morales MA, Aliena-Valero A, Jurado-Rodríguez A, Pérez S, Centeno JM, Miranda FJ, Alborch E, Torregrosa G, Salom JB.J Steroid Biochem Mol Biol. 2017 May 4. pii: S0960-0760(17)30125-5. doi: 10.1016/j.jsbmb.2017.05.001. [Epub ahead of print] PMID: 28479229 2:Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene. Pinkerton JV, Bushmakin AG, Abraham L, Komm BS, Bobula J.Menopause. 2017 May 1. doi: 10.1097/GME.0000000000000888. [Epub ahead of print] PMID: 28463874 3:Bazedoxifene for HRT? [No authors listed]Drug Ther Bull. 2017 Apr;55(4):42-44. doi: 10.1136/dtb.2017.4.0466. PMID: 28408389 4:The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Parish SJ, Gillespie JA.Postgrad Med. 2017 Apr;129(3):340-351. doi: 10.1080/00325481.2017.1281083. Epub 2017 Jan 30. Review. PMID: 28132583 5:Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells. Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, Sugimoto T.Calcif Tissue Int. 2017 Mar;100(3):286-297. doi: 10.1007/s00223-016-0211-x. Epub 2016 Nov 10. PMID: 27832315 6:Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women. Abraham L, Bushmakin AG, Dragon E, Komm BS, Pinkerton JV.Maturitas. 2016 Dec;94:173-179. doi: 10.1016/j.maturitas.2016.09.010. Epub 2016 Sep 16. PMID: 27823739 7:Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Wu X, Cao Y, Xiao H, Li C, Lin J.Mol Cancer Ther. 2016 Nov;15(11):2609-2619. Epub 2016 Aug 17. PMID: 27535971 8:Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women. Kagan R, Komm BS, Ryan KA, Lavenberg J, Yu CR, Pinkerton JV.Menopause. 2016 Nov;23(11):1204-1213. PMID: 27433860 9:Relaxant Effects of the Selective Estrogen Receptor Modulator, Bazedoxifene, and Estrogen Receptor Agonists in Isolated Rabbit Basilar Artery. Castelló-Ruiz M, Salom JB, Fernández-Musoles R, Burguete MC, López-Morales MA, Arduini A, Jover-Mengual T, Hervás D, Torregrosa G, Alborch E.J Cardiovasc Pharmacol. 2016 Oct;68(4):313-321. PMID: 27389095 10:Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials. Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV.J Womens Health (Larchmt). 2016 Nov;25(11):1102-1111. Epub 2016 Sep 27. PMID: 27676118